40
Participants
Start Date
July 29, 2024
Primary Completion Date
December 15, 2025
Study Completion Date
July 15, 2026
Whole Genome Sequencing
Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
RECRUITING
Abu Dhabi Health Research Center, Abu Dhabi
Predictiv Care, Inc.
INDUSTRY
Abu Dhabi Health Services Company
OTHER_GOV